A Comparison Between the Aysis® Cs2 (General Electrics) Ventilator in EtControl® Mode and the Perseus® A 500 (Dräger) in VaporView® Mode on Maniability and Consumption of Desflurane

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02427971

Acronym

ConsoHalo

Enrollment

Registered

2015-04-28

Start date

2015-01-31

Completion date

2015-04-30

Last updated

2015-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthetics Agent, Consumption, Desflurane, Inhalation

Brief summary

The Aysis® Cs2 ventilator offers an automated control of end-tidal inhalation anesthetic concentration, the EtControl® mode. A low Fresh Gas Flow (FGF) (0.5L/min) is kept during the maintenance of the anesthesia, decreasing the expensive consumption of halogenated agents. The Perseus® A 500 offers a VaporView® mode that gives the evolution of inspired (Fi) and end-tidal (Fe) fractions of halogenated agents for 20 minutes based on the delivered fraction (Fd). FGF remains adjusted manually by the practitioner. This mode also makes it possible to maintain a low FGF (0.5 L/min), provided the halogen Fd is set to maintain a steady Fe curve. The goal of this work was to compare the maniability of the intraoperative administered concentrations and the consumption of Desflurane between these 2 modalities of administration.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* patients undergoing a general anesthesia for intra abdominal surgery during more than one hour * ASA 1or 2

Exclusion criteria

* contraindication to halogenated agent * thoracic surgery * no french speaking

Design outcomes

Primary

Measure	Time frame	Description
Consumption of Desflurane between these 2 modalities of administration.	Time of general anesthesia (1h minimum up to 12h)	Des consumption was measured by micrometric weighing of the vaporizer before and after general anesthesia and a milliliter per min consumption was calculated

Secondary

Measure	Time frame	Description
Comparison of inspired (Fi) and end-tidal (Fe) fractions of halogenated evolution	Time of general anesthesia (1h minimum up to 12h)	—
Anesthesia depth monitoring by BIS	Time of general anesthesia (1h up to 12h)	—
Hemodynamic stability	Time of general anesthesia (1h minimum up to 12h)	Number of cardiovascular event which required an intervention * Vasopressive drug * Antihypertensive drug * modification of the Desflurane end-tidal (Fe) fraction

Countries

France

Outcome results